ArticleWorld journal of gastrointestinal oncology2025
Prognostic significance of preoperative C-reactive protein-triglyceride-glucose index in long-term outcomes after radical gastrectomy for gastric cancer.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer, a globally prevalent malignant tumor, continues to exhibit high incidence and mortality rates. Although radical gastrectomy remains the primary treatment for this disease, postoperative complications frequently arise, negatively impacting short-term recovery and significantly reducing patients' quality of life. In this context, accurately predicting the risk of postoperative recurrence and metastasis, coupled with targeted interventions, could substantially improve patient outcomes. The C-reactive protein-triglyceride-glucose index (CTI), a composite biomarker that integrates metabolic disturbances and systemic inflammation, has garnered increasing attention in oncology. The prognostic nutritional index (PNI), a composite measure based on serum albumin and peripheral blood lymphocyte count, is used to evaluate both the nutritional status and systemic immune function of patients. In recent years, both the CTI and PNI have demonstrated significant prognostic value in predicting tumor outcomes, assessing treatment responses, and formulating personalized treatment strategies.
aimTo investigate whether the combined inflammation and insulin resistance marker, the CTI, can serve as a prognostic indicator for patients undergoing radical gastrectomy for gastric cancer. Additionally, it seeks to develop a predictive model by incorporating the PNI alongside CTI.
methodsThis retrospective study included a total of 300 patients who underwent radical gastrectomy. The patients were classified into high and low CTI groups based on their CTI index. Cox proportional hazards regression analysis was performed to identify independent prognostic factors influencing overall survival (OS) and disease-free survival (DFS), and two nomogram models were developed.
resultsOf the included patients, 131 had a high CTI and 169 had a low CTI. The DFS period of the low CTI group was significantly longer than that of the high CTI group. The number of postoperative adjuvant treatments, T stage, N stage, CTI, and PNI were identified as independent prognostic factors for DFS. The hazard ratio for CTI was 2.07 (95% confidence interval: 1.36-3.17,
conclusionCTI is a long-term prognostic indicator for the outcome of radical gastrectomy for gastric cancer. Patients with lower CTI values have a better prognosis. The prediction models constructed by combining CTI with PNI has good predictive ability for DFS and OS after radical gastrectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.